ATE549359T1 - Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen - Google Patents

Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen

Info

Publication number
ATE549359T1
ATE549359T1 AT04725024T AT04725024T ATE549359T1 AT E549359 T1 ATE549359 T1 AT E549359T1 AT 04725024 T AT04725024 T AT 04725024T AT 04725024 T AT04725024 T AT 04725024T AT E549359 T1 ATE549359 T1 AT E549359T1
Authority
AT
Austria
Prior art keywords
antibodies
insulin
receptor
growth factor
igf
Prior art date
Application number
AT04725024T
Other languages
English (en)
Inventor
Yvo Graus
Erhard Kopetzki
Klaus-Peter Kuenkele
Olaf Mundigl
Paul Parren
Frank Rebers
Ralf Schumacher
De Winkel Jan Van
Vugt Martine Van
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE549359T1 publication Critical patent/ATE549359T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04725024T 2003-04-02 2004-04-01 Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen ATE549359T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45983703P 2003-04-02 2003-04-02
US46300303P 2003-04-15 2003-04-15
PCT/EP2004/003442 WO2004087756A2 (en) 2003-04-02 2004-04-01 Antibodies against insulin-like growth factor i receptor and uses thereof

Publications (1)

Publication Number Publication Date
ATE549359T1 true ATE549359T1 (de) 2012-03-15

Family

ID=33135138

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04725024T ATE549359T1 (de) 2003-04-02 2004-04-01 Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen

Country Status (7)

Country Link
US (1) US7378503B2 (de)
EP (1) EP1613658B1 (de)
JP (2) JP4473257B2 (de)
AT (1) ATE549359T1 (de)
CA (1) CA2519113C (de)
ES (1) ES2383014T3 (de)
WO (1) WO2004087756A2 (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316921B1 (de) * 2002-05-24 2014-05-14 Merck Sharp & Dohme Corp. Humaner neutraliserender Anti-IGFR Antikörper
CA2519113C (en) * 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
DK1656391T3 (da) 2003-08-13 2011-01-03 Pfizer Prod Inc Modificerede humane IGF-1R antistoffer
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
JP5848861B2 (ja) * 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
CN101014365B (zh) * 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
MX2007006640A (es) 2004-12-03 2007-06-19 Schering Corp Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0501741D0 (en) * 2005-01-27 2005-03-02 Binding Site The Ltd Antibody
CA2604393A1 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
EP1896505A2 (de) * 2005-06-15 2008-03-12 Schering Corporation Anti-igf1r antikörperformulierungen
PL2100614T3 (pl) 2005-06-17 2014-02-28 Imclone Llc Przeciwciała przeciwko PDGFR alfa do zastosowania w leczeniu guzów nowotworowych
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
EP1981969A4 (de) * 2006-01-19 2009-06-03 Genzyme Corp Gitr-antikörper für die krebsbehandlung
KR101353706B1 (ko) 2006-02-03 2014-02-18 유니버시티 오브 워싱톤 전립선 암 치료용 보강제로서의 ⅰｇｆ-ⅰｒ 길항제
CN101371140B (zh) 2006-03-09 2013-11-13 弗·哈夫曼-拉罗切有限公司 抗药物抗体的测定
RU2008142359A (ru) * 2006-03-28 2010-05-10 Ф.Хоффманн-Ля Рош Аг (Ch) Композиция человеческого моноклонального антитела к igf-1r
JP2009532027A (ja) * 2006-03-28 2009-09-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｉｇｆ−１ｒ抗体およびその使用
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US20080014203A1 (en) * 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
CA2655997A1 (en) 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
EP2221619A1 (de) 2006-09-12 2010-08-25 F. Hoffmann-La Roche AG Verfahren zur Detektion von Antikörpern, gerichted gegen therapeutische Antikörper
EP2104501B1 (de) 2006-12-13 2014-03-12 Merck Sharp & Dohme Corp. Verfahren zur krebsbehandlung mit igf1r-inhibitoren
WO2008098115A2 (en) * 2007-02-07 2008-08-14 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
CA2677901A1 (en) 2007-02-27 2008-09-04 F. Hoffmann-La Roche Ag Method for the assessment of the inhibitory activity of antibodies against insulin-like growth factor i receptor
JP2010520204A (ja) * 2007-03-02 2010-06-10 アムジェン インコーポレイテッド 腫瘍疾患を治療するための方法および組成物
EP2559771A3 (de) 2007-05-17 2013-06-12 Bristol-Myers Squibb Company Biomarker und Verfahren zur Bestimmung der Empfindlichkeit gegen Rezeptor-1-Modulatoren des vaskulären Insulinwachstumsfaktors
JP5570989B2 (ja) * 2007-08-31 2014-08-13 アムジエン・インコーポレーテツド 固体タンパク質製剤
EP2205280B1 (de) * 2007-09-27 2019-09-04 Amgen Inc. Pharmazeutische formulierungen
ES2962777T3 (es) 2007-11-15 2024-03-21 Amgen Inc Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral
SI2573568T1 (sl) 2007-12-15 2015-05-29 F. Hoffmann-La Roche Ag Razlikovalni test
CA2709827A1 (en) * 2007-12-18 2009-06-25 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
CA2758297A1 (en) 2009-04-16 2010-10-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
AU2010275687A1 (en) 2009-07-24 2012-01-12 F. Hoffmann-La Roche Ag Stirrer system
AU2010309931B2 (en) 2009-10-19 2015-08-20 F. Hoffmann-La Roche Ag Non-cross-reactive anti IgG antibodies
AU2010310457B2 (en) 2009-10-23 2015-07-02 Amgen Inc. Vial adapter and system
SI2493922T1 (sl) 2009-10-26 2017-06-30 F. Hoffmann-La Roche Ag Postopek za proizvodnjo glikoziliranega imunoglobulina
US20120220594A1 (en) 2009-10-30 2012-08-30 Bristol-Meyers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
WO2011083391A2 (en) 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
CN103025369B (zh) 2010-06-07 2016-07-06 安姆根有限公司 药物递送装置
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
CA3043423A1 (en) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Anti-human igg1 antibody
RU2591523C2 (ru) 2010-11-05 2016-07-20 Ф. Хоффманн-Ля Рош Аг Оптимизированный метод захвата антител хроматографией смешанного типа
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
WO2012135315A1 (en) 2011-03-31 2012-10-04 Amgen Inc. Vial adapter and system
WO2012145685A1 (en) 2011-04-20 2012-10-26 Amgen Inc. Autoinjector apparatus
PL2723773T3 (pl) 2011-06-22 2018-07-31 F.Hoffmann-La Roche Ag Eliminacja komórek docelowych przez obecne w krążeniu, swoiste dla wirusa, cytotoksyczne limfocyty T z wykorzystaniem kompleksów zawierających MHC klasy I
WO2013056069A1 (en) 2011-10-13 2013-04-18 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
BR122021004411B1 (pt) 2011-10-14 2022-05-10 Amgen Inc Injetor e método de montagem do injetor
WO2013071056A2 (en) 2011-11-11 2013-05-16 Duke University Combination drug therapy for the treatment of solid tumors
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Verfahren zur Herstellung multispezifischer Antikörper
SI3081249T1 (sl) 2012-11-21 2021-03-31 Amgen Inc. Naprava za dajanje zdravila
PL2935328T3 (pl) 2012-12-21 2019-02-28 Hoffmann La Roche Połączone wiązaniem dwusiarczkowym wielowartościowe białka wielofunkcyjne zawierające MHC klasy I
TWI614041B (zh) 2013-03-15 2018-02-11 安美基公司 用於注射器之匣盒
US9868788B2 (en) 2013-03-15 2018-01-16 Wake Forest University Health Sciences Antibodies against human and canine IL-13RA2
ES2853748T3 (es) 2013-03-22 2021-09-17 Amgen Inc Inyector y método de montaje
RU2674996C2 (ru) 2013-07-04 2018-12-14 Ф. Хоффманн-Ля Рош Аг Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки
JP7086520B2 (ja) 2013-10-24 2022-06-20 アムジエン・インコーポレーテツド インジェクター及び組み立ての方法
WO2015061389A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Drug delivery system with temperature-sensitive control
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
SG10201811702TA (en) 2014-05-07 2019-01-30 Amgen Inc Autoinjector with shock reducing elements
US20170098058A1 (en) 2014-06-03 2017-04-06 Amgen Inc. Systems and methods for remotely processing data collected by a drug delivery device
WO2016033509A1 (en) * 2014-08-29 2016-03-03 The Regents Of The University Of Colorado, A Body Corporate Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica
MX2021014323A (es) 2014-10-14 2023-02-02 Amgen Inc Dispositivo de inyección de fármaco con indicadores visuales y audibles.
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
WO2016100781A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with proximity sensor
US10583245B2 (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
CA2929542A1 (en) * 2015-05-13 2016-11-13 Pfizer Inc. Treatment with anti-efna4 antibody-drug conjugates
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
US11200298B2 (en) 2016-03-15 2021-12-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
EP3458988B1 (de) 2016-05-16 2023-10-18 Amgen Inc. Datenverschlüsselung in medizinischen vorrichtungen mit eingeschränkter rechenfähigkeit
EP3465124A1 (de) 2016-06-03 2019-04-10 Amgen Inc. Wirkungstestvorrichtungen und verfahren für wirkstofffreisetzungsvorrichtungen
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
EP3570917A1 (de) 2017-01-17 2019-11-27 Amgen Inc. Injektionsvorrichtungen und zugehörige verfahren zur verwendung sowie anordnung
JP7064501B2 (ja) 2017-02-17 2022-05-10 アムジエン・インコーポレーテツド 無菌流体流路を備える薬物送達デバイスおよび関連する組立方法
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
AU2018231107B2 (en) 2017-03-06 2023-04-20 Amgen Inc. Drug delivery device with activation prevention feature
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
KR102619150B1 (ko) 2017-03-09 2023-12-27 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
EA037969B1 (ru) 2017-03-28 2021-06-17 Эмджен Инк. Система и способ сборки штока поршня и шприца
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
US11904143B2 (en) 2017-06-08 2024-02-20 Amgen Inc. Torque driven drug delivery device
MX2019015472A (es) 2017-06-22 2020-02-19 Amgen Inc Reduccion del impacto/choque de la activacion del mecanismo.
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. ELECTRONIC DRUG DELIVERY DEVICE COMPRISING A CAP ACTIVATED BY A SWITCH ASSEMBLY
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM
US11672733B2 (en) 2017-07-21 2023-06-13 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
EP3658203B1 (de) 2017-07-25 2022-08-31 Amgen Inc. Arzneimittelabgabevorrichtung mit getriebemodul und verwandtes verfahren zur montage
US20200164155A1 (en) 2017-08-09 2020-05-28 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
MA49897A (fr) 2017-08-18 2020-06-24 Amgen Inc Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019046600A1 (en) 2017-08-30 2019-03-07 Amgen Inc. INSULIN-RELATED GROWTH FACTOR 1 RECEPTOR BINDING PROTEINS (IGF-1R) AND METHODS OF USE
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
MA50614A (fr) 2017-10-06 2020-08-12 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
EP3694578A1 (de) 2017-10-09 2020-08-19 Amgen Inc. Arzneimittelabgabevorrichtung mit antriebsanordnung sowie zugehöriges verfahren zur montage
EP3703778A1 (de) 2017-11-03 2020-09-09 Amgen Inc. System und ansätze zum sterilisieren einer arzneimittelabgabevorrichtung
US20200338271A1 (en) 2017-11-06 2020-10-29 Amgen Inc. Fill-finish assemblies and related methods
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
AU2018364933B2 (en) 2017-11-10 2024-01-25 Amgen Inc. Plungers for drug delivery devices
WO2019099322A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Autoinjector with stall and end point detection
EP3710090A1 (de) 2017-11-16 2020-09-23 Amgen Inc. Türverriegelungsmechanismus für wirkstofffreisetzungsvorrichtung
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
US20210369982A1 (en) 2018-07-24 2021-12-02 Amgen Inc. Delivery devices for administering drugs
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
EP3826699A1 (de) 2018-07-24 2021-06-02 Amgen Inc. Ausgabevorrichtung zur verabreichung von arzneimitteln
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
JP2022500095A (ja) 2018-09-24 2022-01-04 アムジエン・インコーポレーテツド インターベンション投薬システム及び方法
WO2020068476A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
AR116679A1 (es) 2018-10-02 2021-06-02 Amgen Inc Sistemas de inyección para la administración de fármacos con transmisión de fuerza interna
JP2022503989A (ja) 2018-10-05 2022-01-12 アムジエン・インコーポレーテツド 投薬量インジケータを有する薬物送達デバイス
US20210346596A1 (en) 2018-10-15 2021-11-11 Amgen Inc. Platform assembly process for drug delivery device
AR116704A1 (es) 2018-10-15 2021-06-02 Amgen Inc Dispositivo de administración de fármacos con mecanismo de amortiguación
EP3873566A1 (de) 2018-11-01 2021-09-08 Amgen Inc. Vorrichtung zur verabreichung von medikamenten mit teilweisem rückzug des medikamentenabgabeelements
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
CA3137360A1 (en) 2019-04-24 2020-10-29 Amgen Inc. Syringe sterilization verification assemblies and methods
JP2022545227A (ja) 2019-08-23 2022-10-26 アムジエン・インコーポレーテツド 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
CN112794912B (zh) * 2021-04-14 2021-07-06 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
BR112023024278A2 (pt) 2021-05-21 2024-01-30 Amgen Inc Método de otimizar uma receita de enchimento para um recipiente de fármacos
WO2023143484A1 (zh) * 2022-01-29 2023-08-03 明慧医药（杭州）有限公司 一种抗原结合蛋白及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
CZ301712B6 (cs) * 2001-01-05 2010-06-02 Pfizer Inc. Protilátka k receptoru IGF-I a farmaceutický prípravek obsahující tuto protilátku
CA2473039C (fr) 2002-01-18 2014-09-23 Pierre Fabre Medicament Nouveaux anticorps anti-igf-ir et leurs applications
EP2316921B1 (de) 2002-05-24 2014-05-14 Merck Sharp & Dohme Corp. Humaner neutraliserender Anti-IGFR Antikörper
CA2519113C (en) * 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof

Also Published As

Publication number Publication date
JP4555385B2 (ja) 2010-09-29
WO2004087756A2 (en) 2004-10-14
US20040228859A1 (en) 2004-11-18
EP1613658A2 (de) 2006-01-11
CA2519113C (en) 2012-06-05
CA2519113A1 (en) 2004-10-14
JP2009213486A (ja) 2009-09-24
JP2006526388A (ja) 2006-11-24
ES2383014T3 (es) 2012-06-15
US7378503B2 (en) 2008-05-27
WO2004087756A3 (en) 2005-01-06
JP4473257B2 (ja) 2010-06-02
EP1613658B1 (de) 2012-03-14

Similar Documents

Publication Publication Date Title
ATE549359T1 (de) Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen
DK1646720T3 (da) Antistoffer mod insulinlignende vækstfaktor I-receptor og anvendelser deraf
JOP20190017B1 (ar) أجسام مضادة ترتبط مع مستقبل cgrp بشري
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
EA201692543A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
IL214325A (en) Antibody against cmet, a drug that includes and uses it
RU2599417C3 (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
PL1648507T3 (pl) Metody i kompozycje powodujące zwiększenie skuteczności przeciwciał terapeutycznych z użyciem związków wzmacniających działanie komórek nk
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
DE602005021694D1 (de) Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung
ATE502053T1 (de) Rekombinanter, tumorspezifischer antikörper und dessen verwendung
NO20072355L (no) Cupredoxinderiverte transportmidler og metoder for fremstilling av disse
MY163480A (en) Sclerostin binding agents
EA201001223A1 (ru) Стабилизированные белковые композиции
ATE505489T1 (de) Tgf-beta-1-spezifische antikörper
ATE514434T1 (de) Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
MX2009012282A (es) Estructuras cristalinas de fragmentos de neuropilina y complejos de neuropilina-anticuerpos.
ATE447570T1 (de) Pyrimidinderivate zur verwendung als vanilloidrezeptorliganden und deren verwendung bei der behandlung von schmerzen
EA200600065A3 (ru) Гидрофобные композиционные и сыпучие материалы, их применение
AU2003304238A8 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
EA200702071A1 (ru) Новые соединения
MX2007013108A (es) Reactivos que enlazan ccx-ckr2.